<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease - MacDonald, JK - 2016 | Cochrane Library</title> <meta content="Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease - MacDonald, JK - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007572.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease - MacDonald, JK - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007572.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007572.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease" name="citation_title"/> <meta content="John K MacDonald" name="citation_author"/> <meta content="john.macdonald@robartsinc.com" name="citation_author_email"/> <meta content="Tran M Nguyen" name="citation_author"/> <meta content="Robarts Clinical Trials" name="citation_author_institution"/> <meta content="Reena Khanna" name="citation_author"/> <meta content="University of Western Ontario" name="citation_author_institution"/> <meta content="Antje Timmer" name="citation_author"/> <meta content="Carl von Ossietzky University of Oldenburg" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD007572.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/11/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007572.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007572.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007572.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [administration &amp; dosage, *therapeutic use]; Antibodies, Monoclonal, Humanized [administration &amp; dosage, *therapeutic use]; Crohn Disease [*therapy]; Injections, Intravenous; Interleukin‐12 [*antagonists &amp; inhibitors, immunology]; Interleukin‐23 [*antagonists &amp; inhibitors, immunology]; Randomized Controlled Trials as Topic; Remission Induction [methods]; Ustekinumab [administration &amp; dosage, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007572.pub3&amp;doi=10.1002/14651858.CD007572.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007572\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007572\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007572.pub3",title:"Anti\\u2010IL\\u201012/23p40 antibodies for induction of remission in Crohn\u0027s disease",firstPublishedDate:"Nov 25, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007572.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007572.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007572.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007572.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007572.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007572.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007572.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007572.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007572.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007572.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1882 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007572.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/appendices#CD007572-sec-0078"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/table_n/CD007572StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/table_n/CD007572StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#CD007572-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>John K MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#CD007572-cr-0003">Tran M Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#CD007572-cr-0004">Reena Khanna</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information#CD007572-cr-0005">Antje Timmer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information/en#CD007572-sec-0082">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 November 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007572.pub3">https://doi.org/10.1002/14651858.CD007572.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007572-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007572-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007572-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007572-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007572-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007572-abs-0001" lang="en"> <section id="CD007572-sec-0001"> <h3 class="title" id="CD007572-sec-0001">Background</h3> <p>Ustekinumab (CNTO 1275) and briakinumab (ABT‐874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin‐12 and interleukin‐23 (IL‐12/23p40), which are involved in the pathogenesis of Crohn's disease. </p> </section> <section id="CD007572-sec-0002"> <h3 class="title" id="CD007572-sec-0002">Objectives</h3> <p>The objectives of this review were to assess the efficacy and safety of anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease. </p> </section> <section id="CD007572-sec-0003"> <h3 class="title" id="CD007572-sec-0003">Search methods</h3> <p>We searched the following databases from inception to 12 September 2016: PubMed, MEDLINE, EMBASE, and the Cochrane Library (CENTRAL). References and conference abstracts were searched to identify additional studies. </p> </section> <section id="CD007572-sec-0004"> <h3 class="title" id="CD007572-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) trials in which monoclonal antibodies against IL‐12/23p40 were compared to placebo or another active comparator in patients with active Crohn's disease were included.  </p> </section> <section id="CD007572-sec-0005"> <h3 class="title" id="CD007572-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened  studies for inclusion and extracted data. Methodological quality was assessed using the Cochrane risk of bias tool. The primary outcome was failure to induce clinical remission, defined as a Crohn's disease activity index (CDAI) of &lt; 150 points. Secondary outcomes included failure to induce clinical improvement, adverse events, serious adverse events, and withdrawals due to adverse events. Clinical improvement was defined as decreases of &gt; 70 or &gt; 100 points in the CDAI from baseline. We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for each outcome. Data were analyzed on an intention‐to‐treat basis. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria. </p> </section> <section id="CD007572-sec-0006"> <h3 class="title" id="CD007572-sec-0006">Main results</h3> <p>Six RCTs (n = 2324 patients) met the inclusion criteria. A low risk of bias was assigned to all studies. The two briakinumab trials were not pooled due to differences in doses and time points for analysis. In both studies there was no statistically significant difference in remission rates. One study (n = 79) compared doses of 1 mg/kg and 3 mg/kg to placebo. In the briakinumab group 70% (44/63) of patients failed to enter clinical remission at 6 or 9 weeks compared to 81% (13/16) of placebo patients (RR 0.86, 95% CI 0.65 to 1.14). Subgroup analysis revealed no significant differences by dose. The other briakinumab study (n = 230) compared intravenous doses of 200 mg, 400 mg and 700 mg with placebo. Eighty‐four per cent (154/184) of briakinumab patients failed to enter clinical remission at six weeks compared to 91% (42/46) of placebo patients (RR 0.92, 95% CI 0.83 to 1.03). Subgroup analysis revealed no significant differences by dose. GRADE analyses of the briakinumab studies rated the overall quality of the evidence for the outcome clinical remission as low. Based on the results of these two studies the manufacturers of briakinumab stopped production of this medication. The ustekinumab studies were pooled despite differences in intravenous doses (i.e. 1mg/kg, 3 mg/kg, 4.5 mg/kg, and 6 mg/kg), however the subcutaneous dose group was not included in the analysis, as it was unclear if subcutaneous was equivalent to intravenous dosing. There was a statistically significant difference in remission rates. At week six, 84% (764/914) of ustekinumab patients failed to enter remission compared to 90% (367/406) of placebo patients (RR 0.92, 95% CI 0.88 to 0.96; 3 studies; high‐quality evidence). Subgroup analysis showed a statistically significant difference for the 6.0 mg/kg dose group (moderate‐quality evidence). There were statistically significant differences in clinical improvement between ustekinumab and placebo‐treated patients. In the ustekinumab group, 55% (502/914) of patients failed to improve clinically (i.e. 70‐point decline in CDAI score), compared to 71% (287/406) of placebo patients (RR 0.78, 95% CI 0.71 to 0.85; 3 studies). Subgroup analysis revealed significant differences compared to placebo for the 1 mg/kg, 4.5 mg/kg and 6 mg/kg dosage subgroups. Similarly for a 100‐point decline in CDAI, 64% (588/914) of patients in the ustekinumab group failed to improve clinically compared to 78% (318/406) of placebo patients (RR 0.82, 95% CI 0.77 to 0.88; 3 studies; high‐quality evidence). Subgroup analysis showed a significant difference compared to placebo for the 4.5 mg/kg and 6.0 mg/kg (high‐quality evidence) dose groups. There were no statistically significant differences in the incidence of adverse events, serious adverse events or withdrawal due to adverse events. Sixty‐two per cent (860/1386) of ustekinumab patients developed at least one adverse event compared to 64% (407/637) of placebo patients (RR 0.97, 95% CI 0.90 to 1.04; 4 studies; high‐quality evidence). Five per cent (75/1386) of ustekinumab patients had a serious adverse event compared to 6% (41/637) of placebo patients (RR 0.83, 95% CI 0.58 to 1.20; 4 studies; moderate‐quality evidence). The most common adverse events in briakinumab patients were injection site reactions and infections. Infections were the most common adverse event in ustekinumab patients. Worsening of Crohn's disease and serious infections were the most common serious adverse events. </p> </section> <section id="CD007572-sec-0007"> <h3 class="title" id="CD007572-sec-0007">Authors' conclusions</h3> <p>High quality evidence suggests that ustekinumab is effective for induction of clinical remission and clinical improvement in patients with moderate to severe Crohn's disease. Moderate to high quality evidence suggests that the optimal dosage of ustekinumab is 6 mg/kg. Briakinumab and ustekinumab appear to be safe. Moderate quality evidence suggests no increased risk of serious adverse events. Future studies are required to determine the long‐term efficacy and safety of ustekinumab in patients with moderate to severe Crohn's disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007572-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007572-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007572-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007572-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007572-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007572-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007572-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007572-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007572-abs-0003" lang="en"> <h3>Ustekinumab and briakinumab for the treatment of active Crohn's disease</h3> <p><b>What is Crohn's disease?</b> <br/> Crohn's disease is a long‐term (chronic) inflammatory bowel disease that can affect any part of the gastrointestinal tract from mouth to anus. Symptoms include abdominal pain, non‐bloody diarrhoea, and weight loss. </p> <p><b>What are ustekinumab and briakinumab?</b> <br/> Ustekinumab and briakinumab are biologic medications. These medications can be injected under the skin using a syringe or directly infused into a vein (intravenous). Biologic therapies suppress the immune system and reduce the inflammation associated with Crohn's disease. When people with Crohn's disease are experiencing symptoms of the disease it is said to be ‘active’; periods when the symptoms stop are called ‘remission’. </p> <p><b>What did the researchers investigate?</b> <br/> The researchers investigated whether ustekinumab or briakinumab produce remission in people with active Crohn's disease; and whether these medications cause any harms (side effects). The researchers searched the medical literature up to 12 September 2016. </p> <p><b>What did the researchers find?</b> <br/> The researchers identified six studies that included a total of 2324 participants. Two studies compared briakinumab to placebo (a fake medicine) and four studies compared ustekinumab to placebo. All of the studies were high quality. </p> <p>There was no difference in the proportion of briakinumab and placebo participants who achieved remission. An increase in side effects or severe side effects were not seen with briakinumab compared to placebo. The most common side effects in briakinumab participants were reactions at the site of injection and infections. Based on the results of these two studies the manufacturers of briakinumab stopped production of this medication. </p> <p>High quality evidence suggests that ustekinumab is better than placebo for helping participants achieve remission and for reducing symptoms of active Crohn's disease. Different doses of ustekinumab were investigated and moderate to high quality suggests that 6.0 mg/kg is the most effective dose. An increase in side effects or serious side effects was not seen with ustekinumab compared to placebo. Infections were the most common adverse event in ustekinumab patients. Worsening of Crohn's disease and serious infections were the most common serious side effects in the ustekinumab studies. Ustekinumab is a promising as a therapy for inducing remission and improving symptoms in people with Crohn's disease. Further studies are required to determine the long‐term effectiveness and safety of ustekinumab in patients with moderate to severe Crohn's disease. The ideal dose of ustekinumab also needs to be determined. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007572-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007572-sec-0073"></div> <h3 class="title" id="CD007572-sec-0074">Implications for practice</h3> <section id="CD007572-sec-0074"> <p>High quality evidence suggests that ustekinumab is effective for induction of clinical remission and improvement in patients with moderate to severe Crohn's disease. Moderate to high quality evidence suggests that the optimal dosage of ustekinumab is 6 mg/kg. Ustekinumab appears to be safe. Moderate quality evidence suggests no increased risk of serious adverse events in patients receiving ustekinumab. Production of briakinumab was stopped by the manufacturer because the primary endpoint for remission was not reached. </p> </section> <h3 class="title" id="CD007572-sec-0075">Implications for research</h3> <section id="CD007572-sec-0075"> <p>Further studies are required to determine the long‐term efficacy and safety of ustekinumab in patients with moderate to severe CD. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007572-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007572-sec-0022"></div> <div class="table" id="CD007572-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Briakinumab compared to placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Briakinumab compared to placebo for induction of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> induction of remission in Crohn's disease<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Briakinumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Briakinumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce clinical remission</b> </p> <p><b>(Mannon 2004)</b> <br/> CDAI (≤150 points)<br/> Follow‐up: 9 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>812 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>699 per 1000</b> <br/> (528 to 926) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.65 to 1.14) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical remission</b> </p> <p><b>(Panaccione 2010)</b> <br/> CDAI (≤150 points)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>913 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b> </p> <p>(758 to 940)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.83 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce clinical response</b> <br/> <b>(Mannon 2004)</b> </p> <p>CDAI ‐ (≥100 point reduction)<br/> Follow‐up: 9 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>688 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>447 per 1000</b> <br/> (289 to 681) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> <br/> (0.42 to 0.99) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response</b> <br/> <b>(Panaccione 2010)</b> </p> <p>CDAI ‐ (≥100 point reduction)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>783 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> </p> <p>(525 to 775)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> </p> <p>(0.67 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p><b>(Panaccione 2010)</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>783 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>705 per 1000</b> </p> <p>(587 to 838)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> </p> <p>(0.75 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>230</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p><b>(Panaccione 2010)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> <br/> (15 to 140) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b> <br/> (0.17 to 1.61) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse event**</b> </p> <p><b>(Pannaccione 2010)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> <br/> (6 to 146) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> <br/> (0.14 to 3.31) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Subject numbers are higher than those reported for the efficacy analyses of the individual studies due to the 200 mg, i.v. experimental group discontinuing enrolment during the induction phase due to poor patient enrolment (Panaccione, 2010). These patients were not included in the efficacy analyses, but were included in the safety analyses.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to sparse data (57 events)<br/> <sup>3</sup> Downgraded on level because the 95% CI around the effect estimate includes both benefit and no effect<br/> <sup>4</sup> Downgraded one level due to sparse data (196 events)<br/> <sup>5</sup> Downgraded two levels due to very sparse data (39 events)<br/> <sup>6</sup> Downgraded one level due to sparse data (153 events)<br/> <sup>7</sup> Downgraded one level due to sparse data (177 events)<br/> <sup>8</sup> Downgraded two levels due to very sparse data (13 events)<br/> <sup>9</sup> Downgraded two levels due to very sparse data (8 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD007572-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ustekinumab compared to placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ustekinumab compared to placebo for induction of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with induction of remission in Crohn's disease<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Ustekinumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ustekinumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical remission</b> <br/> CDAI (≤ 150)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>904 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>832 per 1000</b> <br/> (795 to 868) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> <br/> (0.88 to 0.96) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1320<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity analysis excluding UNITI‐2 trial. These patients had more severe disease at study entry </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical remission (6 mg/kg subgroup)</b> <br/> CDAI (≤ 150)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>907 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>835 per 1000</b> <br/> (789 to 880) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> <br/> (0.87 to 0.97) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>916<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response</b> <br/> CDAI (≥100 point reduction)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>783 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>642 per 1000</b> <br/> (603 to 689) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b> <br/> (0.77 to 0.88) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1320<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis excluding UNITI‐2 trial. These patients had more severe disease at study entry </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response (6 mg/kg subgroup)</b> <br/> CDAI (≥100 point reduction)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>780 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>647 per 1000</b> <br/> (601 to 710) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b> <br/> (0.77 to 0.91) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>916<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>639 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>620 per 1000</b> <br/> (575 to 664) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.97</b> <br/> (0.9 to 1.04) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2023<br/> (4 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> <br/> (37 to 77) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/> (0.58 to 1.2) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2023<br/> (4 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse event</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (10 to 57) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b> <br/> (0.18 to 1.05) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>657<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Subject numbers are higher than those reported for the efficacy analyses of the individual studies due to the omission of efficacy results for subjects receiving subcutaneous placebo and 90 mg ustekinumab, as well as subjects receiving 90mg s.c. and 4.5 mg/kg of ustekinumab in the open‐label arm of the study by Sandborn (2008). The results of these subjects were included in the safety analyses.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to heterogeneity detected for 6 mg/kg subgroup (I<sup>2</sup> = 39%)<br/> <sup>3</sup> Downgraded one level due to sparse data (116 events)<br/> <sup>4</sup> Downgraded two levels due to very sparse data (20 events) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007572-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007572-sec-0023"></div> <section id="CD007572-sec-0024"> <h3 class="title" id="CD007572-sec-0024">Description of the condition</h3> <p>Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract that typically presents with abdominal pain, diarrhoea, and weight loss.  In North America and Northern Europe, Crohn's disease affects up to 320 people per 100,000 (<a href="./references#CD007572-bbs2-0038" title="MolodeckyNA , SoonIS , RabiDM , GhaliWA , FerrisM , ChernoffG , et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;142(1):46‐54.e42; quiz e30. [PUBMED: 22001864] ">Molodecky 2012</a>). Long‐term transmural inflammation can result in complications including stenoses and fistulas that require surgical management in up to a third of patients (<a href="./references#CD007572-bbs2-0053" title="SolbergIC , VatnMH , HoieO , StrayN , SauarJ , JahnsenJ , et al. Clinical course in Crohn's disease: results of a Norwegian population‐based ten‐year follow‐up study. Clinical Gastroenterology and Hepatology2007;5(12):1430‐8. ">Solberg 2007</a>). Therapy is aimed at inducing and maintaining remission and preventing complications. </p> <p>Corticosteroids were among the first available therapies for induction of remission in Crohn's disease (<a href="./references#CD007572-bbs2-0054" title="SummersRW , SwitzDM , SessionsJTJr , BecktelJM , BestWR , KernFJr , et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77(4 Part 2):847‐69. ">Summers 1979</a>; <a href="./references#CD007572-bbs2-0047" title="RutgeertsP , LöfbergR , MalchowH , LamersC , OlaisonG , JewellD , et al. A comparison of budesonide with prednisolone for active Crohn's disease. New England Journal of Medicine1994;331(13):842‐5. ">Rutgeerts 1994</a>). However, persistent remission (<a href="./references#CD007572-bbs2-0022" title="FaubionWAJr , LoftusEVJr , HarmsenWS , ZinsmeisterAR , SandbornWJ . The natural history of corticosteroid therapy for inflammatory bowel disease: a population‐based study. Gastroenterology2001;121(2):255‐60. [PUBMED: 11487534] ">Faubion 2001</a>) and mucosal healing (<a href="./references#CD007572-bbs2-0037" title="ModiglianiR , MaryJY , SimonJF , CortotA , SouleJC , GendreJP , et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology1990;98(4):811‐8. ">Modigliani 1990</a>) have not been observed with corticosteroid therapy. Moreover, these drugs cause multiple adverse effects (<a href="./references#CD007572-bbs2-0023" title="FordAC , BernsteinCN , KhanKJ , AbreuMT , MarshallJK , TalleyNJ , et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology2011;106(4):590‐9. ">Ford 2011</a>; <a href="./references#CD007572-bbs2-0057" title="YangYX , LichtensteinGR . Corticosteroids in Crohn's disease. American Journal of Gastroenterology2002;97(4):803‐23. ">Yang 2002</a>). </p> <p>The immunosuppressives azathioprine, 6‐mercaptopurine and methotrexate have been widely used as corticosteroid‐sparing agents in the treatment of Crohn’s disease (<a href="./references#CD007572-bbs2-0036" title="McDonaldJWD , TsoulisDJ , MacDonaldJK , FeaganBG . Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD003459.pub3] ">McDonald 2012</a>; <a href="./references#CD007572-bbs2-0015" title="ChandeN , TsoulisDJ , MacDonaldJK . Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] ">Chande 2013</a>). Although azathioprine is not effective for inducing remission (<a href="./references#CD007572-bbs2-0015" title="ChandeN , TsoulisDJ , MacDonaldJK . Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] ">Chande 2013</a>), it is beneficial when used in combination with infliximab therapy (<a href="./references#CD007572-bbs2-0019" title="ColombelJF , SandbornWJ , ReinischW , MantzarisGJ , KornbluthA , RachmilewitzD , et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine2010;362(15):1383‐95. ">Colombel 2010</a>; <a href="./references#CD007572-bbs2-0015" title="ChandeN , TsoulisDJ , MacDonaldJK . Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] ">Chande 2013</a>). However, azathioprine requires careful monitoring for adverse events including pancreatitis, liver toxicity, and neutropenia (<a href="./references#CD007572-bbs2-0044" title="RajLS , HawthorneAB . Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterology2010;1:44‐51. ">Raj 2010</a>). </p> <p>Due to the limited efficacy and potential toxicities of those drugs, monoclonal antibodies directed against tumor necrosis factor alpha (TNF‐α) were developed as more selective therapeutic agents. TNF‐α antagonists, which include infliximab, adalimumab, and certolizumab pegol, are effective for both induction and maintenance of remission in Crohn’s disease (<a href="./references#CD007572-bbs2-0055" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.. New England Journal of Medicine1997;337(15):1029‐35. ">Targan 1997</a>; <a href="./references#CD007572-bbs2-0028" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541‐9. ">Hanauer 2002</a>; <a href="./references#CD007572-bbs2-0012" title="AkobengAK , ZachosM . Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD003574.pub2] ">Akobeng 2003</a>; <a href="./references#CD007572-bbs2-0029" title="HanauerSB , SandbornWJ , RutgeertsP , FedorakRN , LukasM , MacIntoshD , et al. Human anti‐tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC‐I trial. Gastroenterology2006;130(2):323‐33. ">Hanauer 2006</a>; <a href="./references#CD007572-bbs2-0034" title="LawsonMM , ThomasAG , AkobengAK . Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005112.pub2] ">Lawson 2006</a>; <a href="./references#CD007572-bbs2-0048" title="SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , MasonD , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. ">Sandborn 2007</a>; <a href="./references#CD007572-bbs2-0049" title="SchreiberS , Khaliq‐KareemiM , LawranceIC , ThomsenOØ , HanauerSB , McColmJ , et al. Maintenance therapy with certolizumab pegol for Crohn's disease. New England Journal of Medicine2007;357(3):239‐50. ">Schreiber 2007</a>). However, concerns regarding infection (<a href="./references#CD007572-bbs2-0017" title="ColombelJF , LoftusEVJr , TremaineWJ , EganLJ , HarmsenWS , SchleckCD , et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology2004;126(1):19‐31. ">Colombel 2004</a>; <a href="./references#CD007572-bbs2-0018" title="ColombelJF , SandbornWJ , RutgeertsP , EnnsR , HanauerSB , PanaccioneR , et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132(1):52‐65. ">Colombel 2007</a>; <a href="./references#CD007572-bbs2-0049" title="SchreiberS , Khaliq‐KareemiM , LawranceIC , ThomsenOØ , HanauerSB , McColmJ , et al. Maintenance therapy with certolizumab pegol for Crohn's disease. New England Journal of Medicine2007;357(3):239‐50. ">Schreiber 2007</a>; <a href="./references#CD007572-bbs2-0051" title="SinghJA , WellsGA , Christensen , GhogomuET , MaxwellL , MacDonaldJK , et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane database of systematic reviews2011;2:CD008794. ">Singh 2011</a>) and a potentially increased risk of certain types of cancer such as non‐Hodgkin's lymphoma and non‐melanoma skin cancer exists (<a href="./references#CD007572-bbs2-0014" title="BurmesterGR , PanaccioneR , GordonKB , McIlraithMJ , LacerdaAP . Adalimumab: long‐term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases2013;72(4):517‐24. ">Burmester 2013</a>; <a href="./references#CD007572-bbs2-0032" title="HudesmanD , LichtigerS , SandsB . Risk of extraintestinal solid cancer with anti‐TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflammatory Bowel Diseases2013;19(3):644‐649. ">Hudesman 2013</a>). Furthermore, primary and secondary failure of TNF‐α antagonists occurs in approximately 30 and 40% of patients, respectively (<a href="./references#CD007572-bbs2-0055" title="TarganSR , HanauerSB , vanDeventerSJ , MayerL , PresentDH , BraakmanT , et al. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.. New England Journal of Medicine1997;337(15):1029‐35. ">Targan 1997</a>; <a href="./references#CD007572-bbs2-0028" title="HanauerSB , FeaganBG , LichtensteinGR , MayerLF , SchreiberS , ColombelJF , et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359(9317):1541‐9. ">Hanauer 2002</a>; <a href="./references#CD007572-bbs2-0029" title="HanauerSB , SandbornWJ , RutgeertsP , FedorakRN , LukasM , MacIntoshD , et al. Human anti‐tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC‐I trial. Gastroenterology2006;130(2):323‐33. ">Hanauer 2006</a>; <a href="./references#CD007572-bbs2-0020" title="DaneseS , FiorinoG , ReinischW . Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti‐TNF‐α therapy. Alimentary Pharmacology and Therapeutics2011;34(1):1‐10. ">Danese 2011</a>). These limitations provided the impetus to investigate drugs that target different inflammatory pathways. </p> </section> <section id="CD007572-sec-0025"> <h3 class="title" id="CD007572-sec-0025">Description of the intervention</h3> <p>Ustekinumab (CNTO 1275) and briakinumab (ABT‐874) are fully human IgG1 monoclonal antibodies that target the common p40 subunit of the cytokines interleukin‐12 and interleukin‐23 (IL‐12/23p40). Ustekinumab and briakinumab are effective for the treatment of psoriasis (<a href="./references#CD007572-bbs2-0041" title="PappKA , LangleyRG , LebwohlM , KruegerGG , SzaparyP , YeildingN , et al. Efficacy and safety of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with psoriasis: 52‐week results from a randomised, double‐blind, placebo‐controlled trial (PHOENIX 2). Lancet2008;371(9625):1675‐84. [PUBMED: 18486740] ">Papp 2008</a>; <a href="./references#CD007572-bbs2-0025" title="GottliebA , MenterA , MendelsohnA , ShenYK , LiS , GuzzoC , et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double‐blind, placebo‐controlled, crossover trial. Lancet2009;373(9664):633‐40. [PUBMED: 19217154] ">Gottlieb 2009</a>; <a href="./references#CD007572-bbs2-0045" title="ReichK , LangleyRG , PappKA , OrtonneJP , UnnebrinkK , KaulM , et al. A 52‐week trial comparing briakinumab with methotrexate in patients with psoriasis. New England Journal of Medicine2011;365(17):1586‐96. ">Reich 2011</a>), and early Phase I and II clinical trials of ustekinumab suggest a similar benefit in Crohn's disease (<a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>). </p> </section> <section id="CD007572-sec-0026"> <h3 class="title" id="CD007572-sec-0026">How the intervention might work</h3> <p>Crohn's disease is characterized by dysregulated T‐cell activity. Interleukin‐12 (IL‐12) and IL‐23 are released by antigen presenting cells to trigger an acquired immune response (<a href="./references#CD007572-bbs2-0056" title="WatanabeT , KitaniA , MurrayPJ , StroberW . NOD2 is a negative regulator of Toll‐like receptor 2‐mediated T helper type 1 responses. Nature Immunology2004;5(8):800‐8. ">Watanabe 2004</a>; <a href="./references#CD007572-bbs2-0043" title="PelusoI , PalloneF , MonteleoneG . Interleukin‐12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World Journal of Gastroenterology2006;12(35):5606‐10. ">Peluso 2006</a>; <a href="./references#CD007572-bbs2-0013" title="BensonJM , SachsCW , TreacyG , ZhouH , PendleyCE , BrodmerkelCM , et al. Therapeutic targeting of the IL‐12/23 pathways: generation and characterization of ustekinumab. Nature Biotechnology2011;29(7):615‐24. ">Benson 2011</a>; <a href="./references#CD007572-bbs2-0021" title="DuvalletE , SemeranoL , AssierE , FalgaroneG , BoissierMC . Interleukin‐23: a key cytokine in inflammatory diseases. Annals of Medicine2011;43(7):503‐11. ">Duvallet 2011</a>).  Specifically, IL‐12 production stimulates a Th1 response, that culminates in the secretion of the pro‐inflammatory cytokines IFN‐ɣ and TNF‐α (<a href="./references#CD007572-bbs2-0043" title="PelusoI , PalloneF , MonteleoneG . Interleukin‐12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World Journal of Gastroenterology2006;12(35):5606‐10. ">Peluso 2006</a>; <a href="./references#CD007572-bbs2-0013" title="BensonJM , SachsCW , TreacyG , ZhouH , PendleyCE , BrodmerkelCM , et al. Therapeutic targeting of the IL‐12/23 pathways: generation and characterization of ustekinumab. Nature Biotechnology2011;29(7):615‐24. ">Benson 2011</a>; <a href="./references#CD007572-bbs2-0016" title="Cingoz , O . Ustekinumab. Monoclonal Antibodies2011;1(3):216‐221. ">Cingoz 2011</a>). Similarly, IL‐23 stimulates proliferation of Th17 lymphocytes which play a role in many chronic inflammatory conditions (<a href="./references#CD007572-bbs2-0021" title="DuvalletE , SemeranoL , AssierE , FalgaroneG , BoissierMC . Interleukin‐23: a key cytokine in inflammatory diseases. Annals of Medicine2011;43(7):503‐11. ">Duvallet 2011</a>). At a cellular level inhibition of IL‐12/23p40 leads to apoptosis of T cells in the gut mucosa (<a href="./references#CD007572-bbs2-0024" title="FussIJ , MarthT , NeurathMF , PearlsteinGR , JainA , StroberW . Anti‐interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology1999;117(5):1078‐88. [PUBMED: 10535870] ">Fuss 1999</a>). Furthermore, blockade IL‐12 and IL‐23, results in disease improvement in murine models of colitis (<a href="./references#CD007572-bbs2-0039" title="NeurathMF , FussI , KelsallBL , StuberE , StroberW . Antibodies to interleukin 12 abrogate established experimental colitis in mice. Journal of Experimental Medicine1995;182(5):1281‐90. [PUBMED: 7595199] ">Neurath 1995</a>). Collectively, these data suggest a possible therapeutic role for IL‐12/23p40 antibodies for the treatment of Crohn’s disease. </p> </section> <section id="CD007572-sec-0027"> <h3 class="title" id="CD007572-sec-0027">Why it is important to do this review</h3> <p>Ustekinumab, a humanized monoclonal antibody directed against the p40 subunit of IL‐12 and IL‐23, has been more thoroughly investigated in the treatment of psoriasis where it appears to be safe and effective (<a href="./references#CD007572-bbs2-0026" title="GottliebAB , KalbRE , LangleyRG , KruegerGG , deJongEM , GuentherL , et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. Journal of Drugs in Dermatology2014;13(12):1441‐8. ">Gottlieb 2014</a>; <a href="./references#CD007572-bbs2-0042" title="PappKA , GriffithsCE , GordonK , LebwohlM , SzaparyPO , WasfiY , et al. Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up.. British Journal of Dermatology2013;168(4):844‐54. ">Papp 2013</a>). This systematic review summarizes the current evidence regarding the use of anti IL‐12/23p40 antibodies for induction of remission in Crohn's disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007572-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007572-sec-0028"></div> <p>The objectives of this review were to determine the efficacy and safety of anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007572-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007572-sec-0029"></div> <section id="CD007572-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007572-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) that assessed the efficacy and safety of antibodies directed against the p40 subunit of IL‐12 and IL‐23 compared to placebo or other active treatments for induction of remission in Crohn's disease were considered for inclusion. </p> </section> <section id="CD007572-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants were required to have active Crohn's disease defined by conventional clinical, radiological or endoscopic criteria. No age restrictions were applied. </p> </section> <section id="CD007572-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Interventions that involved the administration of an antibody directed against the p40 subunit of IL‐12 and IL‐23 were considered for inclusion. Interventions that altered IL‐12 or IL‐23 by another strategy, such as direct inhibition of transcription were not included (<a href="./references#CD007572-bbs2-0008" title="SandsBE , JacobsonEW , SylwestrowiczT , YounesZ , DrydenG , FedorakR , et al. Randomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflammatory Bowel Diseases2010;16(7):1209‐18. ">Sands 2010</a>). </p> </section> <section id="CD007572-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD007572-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure was the proportion of patients who failed to enter clinical remission, as defined by the original studies (e.g. a Crohn's Disease Activity Index (CDAI) score of &lt; 150)). An intention‐to‐treat analysis was used. </p> </section> <section id="CD007572-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcome measures included:</p> <p> <ul id="CD007572-list-0001"> <li> <p>clinical response;</p> </li> <li> <p>endoscopic remission;</p> </li> <li> <p>steroid withdrawal;</p> </li> <li> <p>adverse events;</p> </li> <li> <p>serious adverse events; and</p> </li> <li> <p>withdrawal due to adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD007572-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007572-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched PubMed, MEDLINE (OvidSP), EMBASE (Ovid SP), and the Cochrane Library (CENTRAL) from inception to 12 September 2016. The search strategies are listed in <a href="./appendices#CD007572-sec-0079">Appendix 1</a>. Conference abstracts from Digestive Disease Week and the United European Gastoenterology Week were also searched to identify abstract publications. </p> </section> <section id="CD007572-sec-0039"> <h4 class="title">Searching other resources</h4> <section id="CD007572-sec-0040"> <h5 class="title">Reference lists</h5> <p>Manual searches of reference lists from potentially relevant papers were performed in order to identify additional studies that may have been missed using the computer‐assisted search strategy. </p> </section> <section id="CD007572-sec-0041"> <h5 class="title">Correspondence</h5> <p>Leaders in the field (W. Strober, P. Mannon, W. Sandborn) were contacted to identify other studies, which may not be published. The manufacturers of briakinumab and ustekinumab (Abbott Laboratories, Abbott Park, IL, USA and Centocor, Horsham, PA, USA) were contacted for additional data. </p> </section> <section id="CD007572-sec-0042"> <h5 class="title">Trial databases</h5> <p>The trial databases clinicaltrials.gov, clinicaltrials.ifpma.org and the meta register of controlled trials at controlled‐trials.com were searched to identify other studies that had not been reported. </p> </section> </section> </section> <section id="CD007572-sec-0043"> <h3 class="title" id="CD007572-sec-0043">Data collection and analysis</h3> <section id="CD007572-sec-0044"> <h4 class="title">Selection of studies</h4> <p>All publications identified by the search strategy were assessed independently by two authors (TN and JKM), and relevant studies were selected according to the inclusion criteria. Disagreements were resolved by consensus. </p> </section> <section id="CD007572-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>Data were extracted independently by two authors (TN and JKM) using standardized extraction sheets. Information was extracted on data source; participants (age range, exclusion criteria, pre‐treatment medication, co‐medication, disease entity, activity); details of intervention (type of antibody, frequency and duration of treatment) and comparison treatment; outcomes studied and duration of follow up; study design features (including method of allocation, concealment, where applicable; intention‐to‐treat analysis); and results, including adverse events and loss to follow up. Discrepancies in the data extractions were resolved by consensus. Investigators were contacted for additional information when data were not available or unclear. </p> </section> <section id="CD007572-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Cochrane risk of bias tool to assess the methodological quality of the included studies (<a href="./references#CD007572-bbs2-0030" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">HIggins 2011a</a>). Two authors independently assessed the risk of bias (TN and JKM). The following study characteristics were assessed: </p> <p> <ol id="CD007572-list-0002"> <li> <p>Randomization sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding of participants, outcome assessors and investigators;</p> </li> <li> <p>Incomplete outcome reporting (i.e. there was an acceptable method of dealing with attrition); </p> </li> <li> <p>Selective outcome reporting (i.e. all outcomes described in the methods were included in the analysis); and </p> </li> <li> <p>Other potential sources of bias.</p> </li> </ol> </p> <p>Based on these characteristics, studies were judged to have a high, low or unclear risk of bias. </p> <p>We used the GRADE approach to assess the overall quality of evidence for the primary outcome and secondary outcomes including clinical response, adverse events, serious adverse events and withdrawal due to adverse events. Outcomes from pooling of randomized trials start as high quality evidence, but may be downgraded due to: (1) risk of bias, (2) indirectness of evidence, (3) inconsistency (unexplained heterogeneity), (4) imprecision (sparse data), and (5) reporting bias (publication bias). The overall quality of evidence for each outcome was determined after considering each of these elements, and categorized as high quality (i.e. further research is very unlikely to change our confidence in the estimate of effect); moderate quality (i.e. further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate); low quality (i.e. further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate); or very low quality (i.e. we are very uncertain about the estimate) (<a href="./references#CD007572-bbs2-0027" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD007572-bbs2-0050" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). </p> </section> <section id="CD007572-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>Data were analysed using Review Manager 5 (<a href="./references#CD007572-bbs2-0046" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. ">RevMan 5</a>). Data were extracted from the original research articles and converted into 2×2 tables. The definitions of treatment success, remission and clinical improvement were set by the authors of each paper, and the data were combined for analysis only if these definitions were sufficiently similar (determined by consensus). All relevant outcomes in the identified studies were reported as dichotomous data so results were all pooled based on the relative risk (RR), with RR &lt; 1.0 denoting superiority of the experimental treatment. Results were presented with 95% confidence intervals (CI). The 'Rule of Three' was used to estimate the 95% confidence interval for the frequency of rare, undetected adverse events, i.e. if no events were detected in n trial participants, the upper limit of the 95% confidence interval for the probability of the adverse event is 3/n (<a href="./references#CD007572-bbs2-0035" title="LokeYK , PriceD , HerxheimerA , Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Medical Research Methodology2007;7:32. ">Loke 2007</a>). </p> </section> <section id="CD007572-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>For three arm trials with a single placebo group and two treatment dose groups we split the placebo group in half to avoid a unit of analysis error (<a href="./references#CD007572-bbs2-0031" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). In the case of an odd number of patients the groups were split in a way that led to a larger patient number in the placebo group for the lower dose arm in order to avoid overestimating effects in the higher dose arm, which was assumed to be more effective a priori. In order to avoid carry‐over effects we only included the first part of the study (i.e. before the cross‐over) for any cross‐over studies (<a href="./references#CD007572-bbs2-0031" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD007572-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>Missing outcome data were presented using the conservative intention‐to‐treat approach (i.e. all loss to follow up were considered treatment failures). </p> </section> <section id="CD007572-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>Statistical heterogeneity was examined by calculating the I<sup>2</sup> statistic and the Chi<sup>2</sup> test. Subgroup analysis (see below) was applied to explore clinical and methodological sources of heterogeneity. </p> </section> <section id="CD007572-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>For future updates of this review, if there are a sufficient number of included studies (i.e. ≥ 10), we will investigate publication bias by means of a funnel plot (<a href="https://archie.cochrane.org/sections/documents/view?document=E02E101282E26AA2009DC1BBAE303AB7%26format=REVMAN#REF-Egger-1997" target="_blank">Egger 1997</a>). Publication bias was not investigated for the current version of this review due to an insufficient number of studies. </p> </section> <section id="CD007572-sec-0052"> <h4 class="title">Data synthesis</h4> <p>Results for the different antibodies were not combined. Also studies were not combined, if subgroup analysis suggested significant heterogeneity. A fixed‐effect model was applied when no heterogeneity was detected. Otherwise, a random‐effects model was calculated. Data were not pooled when I<sup>2</sup> suggested considerable heterogeneity. </p> </section> <section id="CD007572-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Preplanned subgroup analyses included:</p> <p> <ul id="CD007572-list-0003"> <li> <p>studies investigating children and studies investigating adults;</p> </li> <li> <p>different drug doses and/or routes of administration;</p> </li> <li> <p>studies investigating patients with high disease activity; and</p> </li> <li> <p>studies investigating only patients who failed anti‐TNF‐α therapy.</p> </li> </ul> </p> <p>Due to the low number of studies identified subgroup analyses could only be performed for different drug doses. </p> </section> <section id="CD007572-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses examined the impact of the following variables on the pooled effect: </p> <p> <ul id="CD007572-list-0004"> <li> <p>random‐effects versus fixed‐effect modelling;</p> </li> <li> <p>low risk of bias only versus unclear or high risk of bias; and</p> </li> <li> <p>relevant loss to follow up (&gt; 10%): Best‐case versus worst‐case scenario.</p> </li> </ul> </p> <p>Sensitivity analysis could only be performed for random‐effects versus fixed‐effect modelling. No publication allowed for the simulation of best‐case and worst‐case scenarios. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007572-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007572-sec-0055"></div> <section id="CD007572-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD007572-sec-0057"> <h4 class="title">Results of the search</h4> <p>The literature search conducted on 12 September 2016 identified 183 records. After duplicates were removed, a total of 139 records were screened for inclusion. Of these, 16 studies were selected for full text review. Two studies were excluded leaving 27 reports of 6 trials (total 2324 patients) that met the pre‐defined inclusion criteria (See <a href="#CD007572-fig-0001">Figure 1</a>). Leaders in the field and the manufacturers of briakinumab and ustekinumab were contacted and no additional studies were identified. </p> <div class="figure" id="CD007572-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007572-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007572-sec-0058"> <h4 class="title">Included studies</h4> <p>All studies were multicenter randomized placebo‐controlled trials investigating patients with active Crohn's disease. The six studies investigated different anti‐IL12/23 antibodies. <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> and <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> investigated briakinumab and four studies investigated ustekinumab (<a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>; <a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>). See <a href="./references#CD007572-sec-0088" title="">Characteristics of included studies</a> for further details. </p> <p><a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> investigated two different doses (1.0 mg and 3.0 mg/kg body weight) of briakinumab administered as 7 weekly subcutaneous injections against placebo. Each group was further randomized to uninterrupted therapy or a 4 week interval between the first and second doses. Follow‐up in this study was between 24 and 27 weeks. As the different dosing regimens differed only slightly, the treatment arms were combined for analysis. The two doses differed markedly with respect to effectiveness and were analysed as separate studies as described in the methods section. </p> <p><a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a> was a Phase IIa study of ustekinumab that compared 4 regimens of ustekinumab to placebo in 104 patients with active CD in both TNF‐α antagonist naive patients and those who had previously failed therapy with one or more of these agents. A sub‐study compared intravenous to subcutaneous therapy for the induction of clinical remission, however this portion of the trial was not included as it was not placebo‐controlled. <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a> utilized a blinded cross‐over design that compared four groups: subcutaneous placebo at weeks 0–3, followed by 90 mg ustekinumab at weeks 8–11; subcutaneous 90 mg ustekinumab at weeks 0–3, then placebo at weeks 8–11; intravenous placebo at week 0, followed by 4.5 mg/kg ustekinumab at week 8; or intravenous 4.5 mg/kg ustekinumab at week 0, then placebo at week 8. Cross‐over to the alternate therapy occurred at week 8. The first part of the cross‐over trial was eligible for inclusion in this review. The subcutaneous doses were not included in the pooled analyses, as it was not clear that this was equivalent to intravenous dosing. </p> <p><a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> was a double‐blind, placebo‐controlled Phase IIb trial in which 246 patients with moderate to severe Crohn’s disease were randomized (1:1:1:3) to placebo, 200 mg briakinumab, 400 mg briakinumab, or 700 mg briakinumab at weeks 0, 4, and 8 weeks.  These patients were stratified by prior TNF‐α antagonist use and response to anti‐TNF‐α therapy. Patients that achieved clinical response at week 12 in the placebo and 400 mg briakinumab groups continued these treatment regimens at weeks 12, 16, 20 in the maintenance phase. Patients with clinical response in the 700 mg briakinumab group were re‐randomized (1:1:1) to placebo, 200 mg IV briakinumab, or 700 mg IV briakinumab for the maintenance phase. The maintenance data were not considered for this systematic review.         </p> <p><a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a> was a double‐blind, placebo‐controlled Phase 2b trial of ustekinumab that randomized 526 patients, of which 524 had previously failed TNF‐α antagonist treatment (99.6%), to receive a single dose of 1, 3, or 6 mg/kg of intravenous ustekinumab or placebo. Patients that responded to ustekinumab were re‐randomized to receive maintenance therapy with 90 mg of subcutaneous ustekinumab or placebo at weeks 8 and 16. The maintenance data were not considered for this systematic review. </p> <p><a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a> was a double‐blind, placebo‐controlled phase III trial of ustekinumab that randomized 741 patients with moderate to severe Crohn's disease, who had failed TNF‐α antagonist therapy, to a single dose of 130 mg or 6mg/kg of ustekinumab or placebo. Patients who responded to ustekinumab were randomized to receive maintenance therapy with 90 mg of subcutaneous ustekinumab (every 8 weeks or every 12 weeks) or placebo through week 40. The maintenance data were not considered for this systematic review. </p> <p><a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a> was a double‐blind, placebo‐controlled phase III trial of ustekinumab that randomized 628 patients with moderate to severe Crohn's disease, who had failed corticosteroids or immunosuppressants or both, to a single dose of 130 mg or 6 mg/kg of ustekinumab or placebo. Patients who responded to ustekinumab were randomized to receive maintenance therapy with 90 mg of subcutaneous ustekinumab (every 8 weeks or every 12 weeks) or placebo through week 40. The maintenance data were not utilized for this systematic review. </p> </section> <section id="CD007572-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies (See <a href="./references#CD007572-sec-0089" title="">Characteristics of excluded studies</a>). <a href="./references#CD007572-bbs2-0007" title="FasanmadeAA , AdedokunOJ , JohannsJR , ZhouH , DavisHM , Blank , M . Pharmacokinetics and exposure‐response relationship of ustekinumab, a human monoclonal antibody to interleukin 12/23 in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;134(4 Suppl 1):A‐490. ">Fasanmade 2008</a> was a pharmacokinetics study that compared intravenous ustekinumab at a dose of 4.5 mg/kg to subcutaneously administered ustekinumab at a dose of 90 mg. The active drug assessed in the <a href="./references#CD007572-bbs2-0008" title="SandsBE , JacobsonEW , SylwestrowiczT , YounesZ , DrydenG , FedorakR , et al. Randomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflammatory Bowel Diseases2010;16(7):1209‐18. ">Sands 2010</a> study was not an antibody directed against the p40 subunit of Il‐12 and IL‐23 (i.e. different mechanism of action than briakinumab and ustekinumab). </p> </section> </section> <section id="CD007572-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias analysis is summarized in <a href="#CD007572-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007572-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: reviewers' judgements about each risk of bias item for each included study." data-id="CD007572-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: reviewers' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007572-sec-0061"> <h4 class="title">Allocation</h4> <p>All six studies utilized computer generated randomization and were rated as low risk of bias for random sequence generation. Five studies used a centralized randomization scheme and were rated as low risk of bias for allocation concealment (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>). The <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> study allocated patients using a telephone based interactive voice response system and was rated as low risk of bias for allocation concealment. </p> </section> <section id="CD007572-sec-0062"> <h4 class="title">Blinding</h4> <p>Five studies utilized an identical placebo and were rated as low risk of bias for blinding (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>). <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> utilized a double‐blind design and reported that, "The study sponsor, site personnel, and patients were unaware of the treatment assignments throughout both the induction and maintenance phases." As a result we rated this study as low risk of bias for blinding. </p> </section> <section id="CD007572-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>All of the studies were rated as low risk for incomplete outcome data. Drop‐outs were generally balanced across treatment groups with similar reasons for withdrawal. </p> </section> <section id="CD007572-sec-0064"> <h4 class="title">Selective reporting</h4> <p>Five studies were rated as low risk for selective reporting (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>). <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> reported on pre‐specified primary and secondary outcomes (safety and efficacy) but only reported on histology and laboratory scores for the treatment group. This study was rated as unclear for selective reporting. </p> </section> <section id="CD007572-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>All of the studies appear to be free of other sources of bias and were rated as low risk of bias for this item. </p> </section> </section> <section id="CD007572-sec-0066"> <h3 class="title" id="CD007572-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD007572-tbl-0001"><b>Summary of findings for the main comparison</b> Briakinumab compared to placebo for induction of remission in Crohn's disease</a>; <a href="./full#CD007572-tbl-0002"><b>Summary of findings 2</b> Ustekinumab compared to placebo for induction of remission in Crohn's disease</a> </p> <p>The two trials of briakinumab were not pooled due to differences in doses and time points for analysis (<a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>; <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>). However in both trials briakinumab was not statistically different than placebo for failure to induce remission. In the <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> (N = 79) study 70% (44/63) of briakinumab patients failed to enter clinical remission at weeks 7 or 9 compared to 81% (13/16) of placebo patients (RR 0.86, 95% CI 0.65 to 1.14). Subgroup analysis showed no statistically significant differences by briakinumab dose (1 mg/kg or 3 mg/kg). No heterogeneity was detected for the dosage subgroup comparison (I<sup>2</sup> = 0%). A GRADE analysis indicated that the quality of evidence supporting the primary outcome was low (See <a href="./full#CD007572-tbl-0001">summary of findings Table for the main comparison</a>). There was a statistically significant difference in the proportion of patients who failed to have a clinical response (&gt; 100 point improvement in CDAI from baseline) favouring briakinumab over placebo. Forty‐four per cent (28/63) briakinumab patients failed to respond to treatment compared to 69% (11/16) of placebo patients (RR 0.65, 95% CI 0.42 to 0.99). Subgroup analysis showed no statistically significant differences by briakinumab dose (1 mg/kg or 3 mg/kg). No heterogeneity was detected for this comparison (I<sup>2</sup> = 0%). Sensitivity analyses utilizing a random‐effects model found similar results for induction of remission and clinical response (See <a href="#CD007572-tbl-0003">Table 1</a>). A GRADE analysis indicated that the quality of evidence supporting the outcome clinical response was low (See <a href="./full#CD007572-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="table" id="CD007572-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity Analysis: Fixed Effects vs. Random Effects Modelling</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fixed Effects Modelling</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random Effects Modelling</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Remission (<a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.86 [0.65, 1.14]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.88 [0.68, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Remission (<a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05 [0.90, 1.22]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.92 [0.83, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ustekinumab /Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94 [0.88, 1.01]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 [0.89, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Response (<a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.65 [0.42, 0.99]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 [0.44, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Response (<a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.82 [0,67, 0.99]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.81 [0.67, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ustekinumab /Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.79 [0.71, 0.89]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.80 [0.72, 0.90]</p> </td> </tr> </tbody> </table> </div> <p>In the <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> (N = 230) study 84% (154/184) of briakinumab patients failed to enter clinical remission compared to 91% (42/46) of placebo patients (RR 0.92, 95% CI 0.83 to 1.03). Subgroup analysis showed no differences by briakinumab dose (400 mg or 700 mg). No heterogeneity was detected for the dosage subgroup comparison (I<sup>2</sup> = 0%). A GRADE analysis indicated that the quality of evidence supporting the primary outcome was low (See <a href="./full#CD007572-tbl-0001">summary of findings Table for the main comparison</a>). There was a difference in clinical response rates (&gt; 100 point improvement in CDAI from baseline) between briakinumab and placebo patients at six weeks. Sixty‐four per cent (117/184) of briakinumab patients failed to respond compared to 78% of placebo patients (RR 0.82 95% CI 0.67 to 0.99). Subgroup analysis showed no differences by briakinumab dose (400 mg or 700 mg). No heterogeneity was detected for this comparison (I<sup>2</sup> = 0%). A GRADE analysis indicated that the quality of evidence supporting this outcome was moderate (See <a href="./full#CD007572-tbl-0001">summary of findings Table for the main comparison</a>). Although all patients completed the induction phase of this study, the sponsor ended the study during the maintenance phase because the primary endpoint was not achieved. Sensitivity analyses utilizing a random‐effects model found similar results for induction of remission and clinical response (See <a href="#CD007572-tbl-0003">Table 1</a>). </p> <p>The ustekinumab trials (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), were pooled despite differences in intravenous doses (i.e. 1mg/kg, 3 mg/kg, 4.5 mg/kg, and 6 mg/kg), however the subcutaneous dose group was not included in the analysis, as it was unclear if subcutaneous was equivalent to intravenous dosing. In the pooled analysis (4 studies, 1947 patients), ustekinumab was statistically different than placebo for failure to induce remission. At week six, 79% (1049/1332) of ustekinumab patients failed to enter remission compared to 88% (539/615) of placebo patients (RR 0.91, 95% CI 0.86 to 0.95; I<sup>2</sup> = 27%). Subgroup analysis showed a difference for the ustekinumab 6.0 mg/kg dose. However a moderate amount of heterogeneity was detected for this subgroup comparison (I<sup>2</sup> = 66%). A visual inspection of the forest plot indicated that the heterogeneity appeared to be a result of the inclusion of the <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a> study in the pooled analysis. The <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a> study differed from the other studies in the pooled analysis because it required objective evidence of active Crohn's disease (e.g. elevated serum C‐reactive protein or fecal calprotectin concentrations or endoscopic ulcerations) for study entry whereas the other studies in the pooled analysis did not. This may be a plausible explanation for the higher response rates seen in the UNITI‐2 patients compared to the other studies in the pooled analysis. To investigate if this study was the source of the heterogeneity the analysis was repeated excluding this trial. The pooled analysis now included 3 studies and 1320 participants. No heterogeneity was detected for the overall comparison (P = 0.72; I<sup>2</sup> = 0%) or for the 6.0 mg/kg subgroup (P 0.20; I<sup>2</sup> = 39%). Eighty‐four per cent (764/914) of ustekinumab patients failed to enter remission at week 6 compared to 90% (367/406) of placebo patients (RR 0.92, 95% CI 0.88 to 0.96). A GRADE analysis indicated that the quality of evidence supporting the primary outcome was high (See <a href="./full#CD007572-tbl-0002">summary of findings Table 2</a>). Subgroup analysis showed a difference in remission rates for the ustekinumab 6.0 mg/kg dose. Eighty‐four per cent (523/625) of ustekinumab 6.0 mg/kg patients failed to enter remission at week 6 compared to 91% (264/291) of placebo patients (RR 0.92, 95% CI 0.88 to 0.96). </p> <p>There were differences in clinical improvement between ustekinumab and placebo treated patients. In the ustekinumab group, 50% (662/1332) of patients failed to achieve a 70‐point decrease in CDAI score, compared to 68% (415/615) of placebo patients (RR 0.73, 95% CI 0.66 to 0.81; I<sup>2</sup> = 30%). Subgroup analysis showed differences in failure to respond for the 1mg/kg, 4.5 mg/kg, and 6 mg/kg dosage subgroups. However, moderate heterogeneity was detected for the 6.0 mg/kg subgroup (I<sup>2</sup> = 64%%). A visual inspection of the forest plot indicated that the heterogeneity appeared to be a result of the inclusion of the <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a> study in the pooled analysis. To investigate if this study was the source of the heterogeneity the analysis was repeated excluding this trial. The pooled analysis now included 3 studies and 1320 participants. No statistically significant heterogeneity was detected for the overall comparison (P = 0.81; I<sup>2</sup> = 0%) or for the 6.0 mg/kg subgroup (P 0.69; I<sup>2</sup> = 0%). Fifty‐five per cent (502/914) of ustekinumab patients failed to achieve a 70‐point decrease in CDAI score at week 6 compared to 71% (287/406) of placebo patients (RR 0.78, 95% CI 0.71 to 0.85). Subgroup analysis showed differences in failure to respond for the 1 mg/kg (RR 0.78, 95% CI 0.61 to 0.98), 4.5 mg/kg (RR 0.59, 95% CI 0.37 to 0.94), and 6 mg/kg (0.78, 95% CI 0.71 to 0.87) dosage subgroups. Similarly for a 100‐point decline in CDAI, 59% (782/1332) of patients in the ustekinumab group failed to have a 100‐point clinical response compared to 76% (467/615) of placebo patients (RR 0.77, 95% CI 0.69 to 0.87; I<sup>2</sup> = 61%). Subgroup analysis showed a difference in failure to respond for the 4.5 mg/kg and 6.0 mg/kg dosage subgroups. However, a high degree of heterogeneity was detected for the 6.0 mg/kg subgroup comparison (I<sup>2</sup> = 80%). A visual inspection of the forest plot indicated that the <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a> study could be the cause of this heterogeneity. To investigate if this study was the source of the heterogeneity the analysis was repeated excluding this trial. The pooled analysis now included 3 studies and 1320 participants. No heterogeneity was detected for the overall comparison (P = 0.57; I<sup>2</sup> = 0%) or for the 6.0 mg/kg subgroup (P 0.72; I<sup>2</sup> = 0%). Sixty‐four per cent (588/914) of ustekinumab patients failed to achieve a 100‐point decrease in CDAI score at week 6 compared to 78% (318/406) of placebo patients (RR 0.82, 95% CI 0.77 to 0.88). A GRADE analysis indicated that the quality of evidence supporting the outcome 100‐point clinical response was high (See <a href="./full#CD007572-tbl-0002">summary of findings Table 2</a>). Subgroup analysis showed a differences in failure to respond for the 4.5 mg/kg (RR 0.59, 95% CI 0.39 to 0.89), and 6 mg/kg (RR 0.83, 95% CI 0.77 to 0.91) dosage subgroups. </p> <p>There were no differences in remission or clinical improvement rates in patients who received subcutaneous ustekinumab or placebo. Seventy‐two per cent (18/25) of patients in the subcutaneous ustekinumab group failed to enter remission at six weeks compared to 77% (20/26) of placebo patients (RR 0.94, 95% CI 0.68 to 1.29). Forty‐eight per cent (12/25) of patients in the subcutaneous ustekinumab group failed to achieve a 70‐point decrease in CDAI at six weeks compared to 62% (16/26) of placebo patients (RR 0.78, 95% CI 0.47 to 1.30). Fifty‐two per cent (13/25) of patients in the subcutaneous ustekinumab group failed to achieve a 100‐point decrease in CDAI at six weeks compared to 65% of placebo patients (RR 0.80, 95% CI 0.50 to 1.27). Sensitivity analyses utilizing a random‐effects model found similar results for induction of remission and clinical response. </p> <p>Endoscopic remission was not assessed in any of the included studies. Steroid withdrawal following treatment was not assessed in any of the included induction studies. <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a> evaluated corticosteroid‐free remission at 22 weeks during the maintenance phase. </p> <p>There was no difference in the proportion of patients who experienced at least one adverse event in the <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> study. Seventy‐one per cent (141/200) of briakinumab patients experienced at least one adverse event compared to 78% (36/46) of placebo patients (RR 0.90, 95% CI 0.75 to 1.07). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was moderate (See <a href="./full#CD007572-tbl-0001">summary of findings Table for the main comparison</a>). <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> did not report on the proportion of patients who had at least one adverse event. <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> reported that injection site reactions were the most common adverse event. Injection site reactions occurred more frequently in the briakinumab groups (77% in the 1mg/kg group and 88% in the 3 mg/kg group) than the placebo group (25%). The majority of these injection site reactions were considered mild (88%). <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> reported infections as the most common adverse event. Thirty‐three per cent of briakinumab patients had an infection compared to 35% of placebo patients. There was no difference in either study in the proportion of patients who developed a serious adverse event or withdrew due to an adverse event. In the <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> study, 11% (7/63) of briakinumab patients had a serious adverse event compared to 12% (2/16) of placebo patients (RR 0.89, 95% CI 0.20 to 3.88). In the <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> study 4% (9/200) of briakinumab patients had a serious adverse event compared to 9% (4/46) placebo patients (RR 0.52, 95% CI 0.17 to 1.61). Three per cent (2/63) of briakinumab patients in the <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> study withdrew due to an adverse event compared to 12% (2/16) placebo patients (RR 0.25, 95% CI 0.04 to 1.67). Three per cent (6/200) of briakinumab patients in the <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> study withdrew due to an adverse event compared to 4% (2/46) of placebo patients (RR 0.69, 95% CI 0.14 to 3.31). GRADE analyses indicated that the overall quality of the evidence supporting the outcomes serious adverse events and withdrawal due to adverse events was low (See <a href="./full#CD007572-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In the ustekinumab studies there was no difference in the proportion of patients who experienced at least one adverse event. Sixty‐two per cent (860/1386) of ustekinumab patients experienced at least one adverse event compared to 64% (407/637) of placebo patients (RR 0.97, 95% CI 0.90 to 1.04; participants = 2023; studies = 4; I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was high (See <a href="./full#CD007572-tbl-0002">summary of findings Table 2</a>). Infections were the most commonly reported adverse event in the ustekinumab studies. Other common adverse events included nasopharyngitis (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), abdominal pain (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), nausea (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), worsening Crohn's disease (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), arthralgia (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), headache (<a href="./references#CD007572-bbs2-0001" title="AdedokunOJ , XuZ , GasinkC , SzaparyP , JohannsJ , GaoLL , et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology2016;150(4 Suppl 1):S408. FeaganBG , SandbornWJ , GasinkC , JacobsteinD , LangY , FriedmanJR , et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine2016. LiK , HaydenK , WadmanE , BhagatS , EmrichS , FriedmanJ , et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology2016;150(4 Suppl 1):S377. SandbornW , GasinkC , BlankM , LangY , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases2016;22(Suppl 1):S1. SandbornW , GasinkC , JacobsteinD , GaoL , JohannsJ , TarganS , et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology2016;150(4 Suppl 1):S982. SandsBE , HanC , GasinkC , SzaparyP , GaoLL , LangY , et al. Ustekinumab improves general health status and disease‐specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials. Gastroenterology150(4 Suppl 1):S1004. ">Feagan 2016 UNITI‐1</a>; <a href="./references#CD007572-bbs2-0002" title="FeaganB , GasinkC , LangY , FriedmanJ , JohannsJ , GaoL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology2016;2016. FeaganB , GasinkC , LangY , FriedmanJR , JohannsJ , GaoLL , et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal2015;3(6):563‐4. ">Feagan 2016 UNITI‐2</a>; <a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>; <a href="./references#CD007572-bbs2-0006" title="DingT , TelescoS , MonastC , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology2016;2016. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology2015;148(4 Suppl 1):S713. DingT , TelescoS , MonastCS , BrodmerkelC , YatsunenkoT , DasA , et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal2015;3(5 Suppl 1):A133‐4. FeaganB , GasinkC , GaoL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology2011;106(Supp 2s):S463. FeaganB , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis2012;6(Supp 1):S129‐30. GasinkC , ChanD , GaoLL , SchenkelB , HanC . Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study. Gastroenterology2013;144(5 Suppl 1):S231. GasinkC , FriedmanJ , GaoL , ChanD , SandbornW , FeaganB . Evaluation of an interim Crohn's disease outcome measure (PRO‐2) based on 2 patient‐reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study. American Journal of Gastroenterology2014;109(Suppl 2s):S497. SandbornWJ , GasinkC , GaoLL , BlankM , JohannsJ , GuzzoC , et al. A multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial. Gastroenterology2011;140(5 Suppl 1):S109. SandbornWJ , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. New England Journal of Medicine2012;367(16):1519‐28. SandsBE , GasinkC , GaoLL , BlankMA , JohannsJ , GuzzoC , et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled phase2b study ofUstekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases2011;17(Supp 2):S24. ToedterG , WuX , GaoLL , GasinkC . Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies. Gastroenterology2011;140(5 Suppl 1):S264. ">Sandborn 2012</a>), and dyspepsia (<a href="./references#CD007572-bbs2-0005" title="SandbornW , FeaganB , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases2008;14(Supp 1):S10. SandbornWJ , FeaganBG , FedorakR , ScherlE , FleisherM , KatzS , et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology2007;132(4 Suppl 1):A51. SandbornWJ , FeaganBG , FedorakRN , ScherlE , FleisherMR , KatzS , et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology2008;135(4):1130‐41. ToedterGP , BlankM , LangY , ChenD , SandbornWJ , deVilliersWJ . Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology2009;104(11):2768‐73. ">Sandborn 2008</a>). </p> <p>There was no difference in the incidence of serious adverse events. Serious adverse events occurred in 5% (75/1386) of ustekinumab patients compared to 6% (41/637) of patients in the placebo group (RR 0.83, 95% CI 0.58 to 1.20; participants = 2023; studies = 4; I<sup>2</sup> = 0%). A GRADE analysis indicated that the overall quality of the evidence supporting this outcome was moderate (See <a href="./full#CD007572-tbl-0002">summary of findings Table 2</a>). Worsening of CD and serious infections were the most common serious adverse events. Although the difference was not statistically significant, more placebo patients withdrew due to adverse events than ustekinumab patients. Five per cent (10/184) of placebo patients withdrew due to adverse events compared to 2% (10/473) of ustekinumab patients (RR 0.44, 95% CI 0.18 to 1.05; participants = 657; studies = 2; I<sup>2</sup> = 0%). </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007572-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007572-sec-0067"></div> <section id="CD007572-sec-0068"> <h3 class="title" id="CD007572-sec-0068">Summary of main results</h3> <p>Briakinumab (ABT‐874) and ustekinumab (CNTO 1275) are monoclonal antibodies that target the shared p40 subunit of IL‐12 and IL‐23, that have been studied for induction of remission in CD. Neither <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> or <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> found briakinumab to be superior to placebo for induction of remission in CD. Grade analyses indicated that the overall quality of the evidence supporting this outcome was low due mostly to sparse data. Both <a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a> and <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> found briakinumab to be superior to placebo for induction of clinical improvement. Grade analyses indicated that the overall quality of the evidence supporting this outcome was low due mostly to sparse data. Subgroup analysis did not identify any significant differences by dose. The <a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a> trial was terminated during the open‐label maintenance phase by the sponsor because the primary endpoint for induction of remission was not achieved, leaving to our knowledge ustekinumab as the only IL‐12/23p40 antagonist currently being investigated for the treatment of CD. </p> <p>Ustekinumab patients were significantly more likely than placebo patients to achieve clinical remission and clinical improvement. Subgroup analysis identified a difference for the 6.0 mg/kg dose group for induction of remission. Clinical improvement results were consistent for both a 70 and 100 point reduction in CDAI scores. Subgroup analysis identified significant differences by dose for 70 (i.e. 1mg/kg, 4.5 mg/kg, and 6 mg/kg dosage subgroups) and 100 point reduction (i.e. 4.5 mg/kg and 6.0 mg/kg subgroups) in CDAI scores. The results of the GRADE analysis indicate that overall quality of the evidence supporting the outcomes clinical remission and 100‐point reduction in CDAI was high. Moderate to high quality evidence suggests that 6.0 mg/kg is the optimal dose for induction of remission and clinical response. Overall these results suggest a therapeutic benefit for ustekinumab in patients with moderate to severe CD. </p> <p>With respect to safety, neither antibody led to an increase in adverse events or serious adverse events. Fewer patients that received anti‐IL‐12/23 monoclonal antibody treatment withdrew due to adverse events than placebo. However, these differences were not statistically significant. This may have been due to greater withdrawal of patients in the placebo group due to recurrence of CD symptoms. Although both drugs demonstrated an acceptable safety profile in these studies, the number of patients investigated did not allow for the assessment of rare adverse events. Studies with long term follow‐up are required to assess the risk of rare adverse events. </p> </section> <section id="CD007572-sec-0069"> <h3 class="title" id="CD007572-sec-0069">Overall completeness and applicability of evidence</h3> <p>The results of this review are applicable to patients with moderate to severe Crohn's disease and patients with moderate to severe Crohn's disease who have failed TNF‐alpha antagonists. High quality evidence suggests that ustekinumab is effective for induction of clinical remission and improvement in patients with moderate to severe Crohn's disease. Ustekinumab offers an out‐of‐class option for patients who fail currently available TNF‐α antagonists. </p> </section> <section id="CD007572-sec-0070"> <h3 class="title" id="CD007572-sec-0070">Quality of the evidence</h3> <p>All of the included studies were judged to be at low risk of bias. GRADE analyses indicated that the overall quality of the evidence supporting the primary and secondary outcomes from the briakinumab studies was moderate to low due mostly to sparse data. GRADE analyses indicated that the overall quality of evidence supporting the primary outcome from the ustekinumab studies was rated as high quality. The secondary outcome clinical response was rated as high quality. Moderate to high quality evidence suggests that 6.0 mg/kg is the optimal dose of ustekinumab for induction of remission and clinical improvement. The outcome adverse events was rated as high quality. The outcome serious adverse events was rated as moderate quality. The outcome withdrawal due to adverse events was rated as low quality due to very sparse data. </p> </section> <section id="CD007572-sec-0071"> <h3 class="title" id="CD007572-sec-0071">Potential biases in the review process</h3> <p>To reduce potential bias in the review process we performed a comprehensive literature search to identify all eligible studies. In addition, two review authors independently assessed studies for inclusion, extracted data and assessed study quality. There are several limitations to this review. The studies that investigated briakinumab were small, thus they were only able to detect large effects and frequent adverse events. </p> </section> <section id="CD007572-sec-0072"> <h3 class="title" id="CD007572-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>The results of our review agree with other published reviews on ustekinumab and briakinumab (<a href="./references#CD007572-bbs2-0033" title="KhannaR , FeaganBG . Ustekinumab for the treatment of Crohn's disease. Immunotherapy2013;5(8):803‐15. ">Khanna 2013</a>; <a href="./references#CD007572-bbs2-0040" title="NiederreiterL , AdolphTE , KaserA . Anti‐IL‐12/23 in Crohn's disease: bench and bedside. Current Drug Targets2013;14(12):1379‐84. ">Niederreiter 2013</a>; <a href="./references#CD007572-bbs2-0052" title="SinghS , GargSK , PardiDS , WangZ , MuradMH , LoftusEVJr . Comparative efficacy of biologic therapy in biologic‐naive patients with Crohn disease: a systematic review and network meta‐analysis. Mayo Clinic Proceedings2014;89(12):1621‐35. ">Singh 2014</a>). Our review is the only systematic review to include a pooled analysis for the ustekinumab studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007572-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007572-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: reviewers' judgements about each risk of bias item for each included study." data-id="CD007572-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: reviewers' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 1 Failure to induce clinical remission (7 &amp; 9 weeks)." data-id="CD007572-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 1 Failure to induce clinical remission (7 &amp; 9 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 2 Failure to Induce clinical remission (6 weeks)." data-id="CD007572-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 2 Failure to Induce clinical remission (6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 3 Failure to induce clinical response (&gt;= 100 points; 7 &amp; 9 weeks)." data-id="CD007572-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 3 Failure to induce clinical response (&gt;= 100 points; 7 &amp; 9 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 4 Failure to induce clinical response (&gt;= 100 points; 6 weeks)." data-id="CD007572-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 4 Failure to induce clinical response (&gt;= 100 points; 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 5 Adverse events." data-id="CD007572-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 6 Serious adverse events." data-id="CD007572-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 6 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Briakinumab versus placebo, Outcome 7 Withdrawals because of adverse events." data-id="CD007572-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Briakinumab versus placebo, Outcome 7 Withdrawals because of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 1 Failure to induce clinical remission (6 weeks)." data-id="CD007572-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 1 Failure to induce clinical remission (6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 2 Failure to induce clinical remission (6 weeks; sensitivity analysis)." data-id="CD007572-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 2 Failure to induce clinical remission (6 weeks; sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 3 Failure to induce clinical response (&gt;= 70 points; 6 weeks)." data-id="CD007572-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 3 Failure to induce clinical response (&gt;= 70 points; 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 4 Failure to induce clinical response (&gt;= 70 points; 6 weeks; sensitivity analysis)." data-id="CD007572-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 4 Failure to induce clinical response (&gt;= 70 points; 6 weeks; sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 5 Failure to Induce clinical response (&gt;=100 points; 6 weeks)." data-id="CD007572-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 5 Failure to Induce clinical response (&gt;=100 points; 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 6 Failure to Induce clinical response (&gt;=100 points; 6 weeks; sensitivity analysis)." data-id="CD007572-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 6 Failure to Induce clinical response (&gt;=100 points; 6 weeks; sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 7 Failure to induce clinical remission ‐ 90 mg, s.c. (6 weeks)." data-id="CD007572-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 7 Failure to induce clinical remission ‐ 90 mg, s.c. (6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 8 Failure to induce clinical response 90 mg s.c. (&gt;= 70 points; 6 weeks)." data-id="CD007572-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 8 Failure to induce clinical response 90 mg s.c. (&gt;= 70 points; 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 9 Failure to induce clinical response 90 mg s.c. (&gt;=100 points; 6 weeks)." data-id="CD007572-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 9 Failure to induce clinical response 90 mg s.c. (&gt;=100 points; 6 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 10 Adverse events." data-id="CD007572-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 10 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 11 Serious adverse events." data-id="CD007572-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 11 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007572-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/urn:x-wiley:14651858:media:CD007572:CD007572-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_t/tCD007572-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Ustekinumab versus placebo, Outcome 12 Withdrawals because of adverse events." data-id="CD007572-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Ustekinumab versus placebo, Outcome 12 Withdrawals because of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/media/CDSR/CD007572/image_n/nCD007572-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007572-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Briakinumab compared to placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Briakinumab compared to placebo for induction of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> induction of remission in Crohn's disease<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Briakinumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Briakinumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce clinical remission</b> </p> <p><b>(Mannon 2004)</b> <br/> CDAI (≤150 points)<br/> Follow‐up: 9 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>812 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>699 per 1000</b> <br/> (528 to 926) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.65 to 1.14) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical remission</b> </p> <p><b>(Panaccione 2010)</b> <br/> CDAI (≤150 points)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>913 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b> </p> <p>(758 to 940)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> </p> <p>(0.83 to 1.03)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failure to induce clinical response</b> <br/> <b>(Mannon 2004)</b> </p> <p>CDAI ‐ (≥100 point reduction)<br/> Follow‐up: 9 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>688 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>447 per 1000</b> <br/> (289 to 681) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> <br/> (0.42 to 0.99) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response</b> <br/> <b>(Panaccione 2010)</b> </p> <p>CDAI ‐ (≥100 point reduction)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>783 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> </p> <p>(525 to 775)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> </p> <p>(0.67 to 0.99)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p><b>(Panaccione 2010)</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>783 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>705 per 1000</b> </p> <p>(587 to 838)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> </p> <p>(0.75 to 1.07)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>230</p> <p>(1 study)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p><b>(Panaccione 2010)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> <br/> (15 to 140) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.52</b> <br/> (0.17 to 1.61) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse event**</b> </p> <p><b>(Pannaccione 2010)</b> <br/> Follow‐up: 12 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> <br/> (6 to 146) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b> <br/> (0.14 to 3.31) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246<br/> (1 study) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Subject numbers are higher than those reported for the efficacy analyses of the individual studies due to the 200 mg, i.v. experimental group discontinuing enrolment during the induction phase due to poor patient enrolment (Panaccione, 2010). These patients were not included in the efficacy analyses, but were included in the safety analyses.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to sparse data (57 events)<br/> <sup>3</sup> Downgraded on level because the 95% CI around the effect estimate includes both benefit and no effect<br/> <sup>4</sup> Downgraded one level due to sparse data (196 events)<br/> <sup>5</sup> Downgraded two levels due to very sparse data (39 events)<br/> <sup>6</sup> Downgraded one level due to sparse data (153 events)<br/> <sup>7</sup> Downgraded one level due to sparse data (177 events)<br/> <sup>8</sup> Downgraded two levels due to very sparse data (13 events)<br/> <sup>9</sup> Downgraded two levels due to very sparse data (8 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Briakinumab compared to placebo for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007572-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ustekinumab compared to placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ustekinumab compared to placebo for induction of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with induction of remission in Crohn's disease<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Ustekinumab<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ustekinumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical remission</b> <br/> CDAI (≤ 150)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>904 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>832 per 1000</b> <br/> (795 to 868) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> <br/> (0.88 to 0.96) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1320<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity analysis excluding UNITI‐2 trial. These patients had more severe disease at study entry </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical remission (6 mg/kg subgroup)</b> <br/> CDAI (≤ 150)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>907 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>835 per 1000</b> <br/> (789 to 880) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> <br/> (0.87 to 0.97) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>916<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response</b> <br/> CDAI (≥100 point reduction)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>783 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>642 per 1000</b> <br/> (603 to 689) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.82</b> <br/> (0.77 to 0.88) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1320<br/> (3 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sensitivity analysis excluding UNITI‐2 trial. These patients had more severe disease at study entry </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Failure to induce clinical response (6 mg/kg subgroup)</b> <br/> CDAI (≥100 point reduction)<br/> Follow‐up: 6 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>780 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>647 per 1000</b> <br/> (601 to 710) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83</b> <br/> (0.77 to 0.91) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>916<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>639 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>620 per 1000</b> <br/> (575 to 664) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.97</b> <br/> (0.9 to 1.04) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2023<br/> (4 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> <br/> (37 to 77) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/> (0.58 to 1.2) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2023<br/> (4 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse event</b> <br/> Follow‐up: 8 weeks </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b><sup>1</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> <br/> (10 to 57) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.44</b> <br/> (0.18 to 1.05) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>657<br/> (2 studies) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Subject numbers are higher than those reported for the efficacy analyses of the individual studies due to the omission of efficacy results for subjects receiving subcutaneous placebo and 90 mg ustekinumab, as well as subjects receiving 90mg s.c. and 4.5 mg/kg of ustekinumab in the open‐label arm of the study by Sandborn (2008). The results of these subjects were included in the safety analyses.<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Control group risk estimates come from control arm of meta‐analysis, based on included trials<br/> <sup>2</sup> Downgraded one level due to heterogeneity detected for 6 mg/kg subgroup (I<sup>2</sup> = 39%)<br/> <sup>3</sup> Downgraded one level due to sparse data (116 events)<br/> <sup>4</sup> Downgraded two levels due to very sparse data (20 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ustekinumab compared to placebo for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007572-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity Analysis: Fixed Effects vs. Random Effects Modelling</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fixed Effects Modelling</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random Effects Modelling</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Remission (<a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.86 [0.65, 1.14]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.88 [0.68, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Remission (<a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.05 [0.90, 1.22]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.92 [0.83, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ustekinumab /Remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.94 [0.88, 1.01]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 [0.89, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Response (<a href="./references#CD007572-bbs2-0003" title="MannonP , FussI , MayerL , ElsonCO , SandbornWJ , DolinB , et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology2004;126(4 Suppl 2):A22‐3. MannonPJ , FussIJ , MayerL , ElsonCO , SandbornWJ , PresentD , et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine2004;351(20):2069‐79. ">Mannon 2004</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.65 [0.42, 0.99]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 [0.44, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Briakinumab /Response (<a href="./references#CD007572-bbs2-0004" title="PanaccioneR , SandbornW , GordonG , LeeS , SafdiA , SedghiS , et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology2010;105(Supp 1):S457‐8. PanaccioneR , SandbornWJ , GordonGL , LeeSD , SafdiA , SedghiS , et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases2015;21(6):1329‐40. ">Panaccione 2015</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.82 [0,67, 0.99]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.81 [0.67, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ustekinumab /Response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.79 [0.71, 0.89]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.80 [0.72, 0.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity Analysis: Fixed Effects vs. Random Effects Modelling</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/full#CD007572-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007572-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Briakinumab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to induce clinical remission (7 &amp; 9 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1 mg/kg body weight each week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 3 mg/kg body weight each week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.48, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Failure to Induce clinical remission (6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IV Infusion of 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IV Infusion of 700 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to induce clinical response (&gt;= 100 points; 7 &amp; 9 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 1 mg/kg body weight each week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.44, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 3 mg/kg body weight each week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.27, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure to induce clinical response (&gt;= 100 points; 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 400 mg iv of briakinumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 700 mg iv of briakinumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals because of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Briakinumab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007572-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ustekinumab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Failure to induce clinical remission (6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.86, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 3.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 4.5 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 6.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Failure to induce clinical remission (6 weeks; sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.88, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 1.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 3.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 4.5 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 6.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Failure to induce clinical response (&gt;= 70 points; 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.66, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 1 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.61, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 3 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 4.5 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 6 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.61, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Failure to induce clinical response (&gt;= 70 points; 6 weeks; sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.71, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 1 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.61, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 3 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 4.5 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 6 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.71, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Failure to Induce clinical response (&gt;=100 points; 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.69, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 1.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 3.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 4.5 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 6.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.63, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Failure to Induce clinical response (&gt;=100 points; 6 weeks; sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 1.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 3.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 4.5 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 6.0 mg/kg IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Failure to induce clinical remission ‐ 90 mg, s.c. (6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Failure to induce clinical response 90 mg s.c. (&gt;= 70 points; 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Failure to induce clinical response 90 mg s.c. (&gt;=100 points; 6 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Withdrawals because of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.18, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ustekinumab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007572.pub3/references#CD007572-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007572.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007572-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007572-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007572-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007572-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD007572-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007572-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007572\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007572\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007572\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007572\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007572\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007572.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007572.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007572.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007572.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007572.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726692663"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007572.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726692667"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007572.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e99dd891f9368',t:'MTc0MDcyNjY5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 